circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
=== Importance in cancer biology === ITGA1 has shown to be an important regulator of cancer progression because malignant cells frequently exploit integrin-mediated ECM signaling to promote survival, invasion, metastasis, and therapy resistance. Dysregulated integrin signaling is associated with tumor development across multiple types of cancer, making ITGA1 a potential biomarker and therapeutic target. In PDAC, ITGA1 contributes to tumor progression by linking collagen-rich ECM environments with intracellular signaling pathways that support EMT, metastatic dissemination and survival. ITGA1 was identified as part of a protein network associated with PDAC progression emphasizing its importance in tumor biology. In retinoblastoma, ITGA1 is a possible therapeutic target because ITGA1 expression promotes the same functions of tumor cells through activation of downstream signaling pathways like FAK and STAT3. Pharmacological or genetic inhibition of ITGA1 reduces tumor progression, exhibiting the potential importance of targeting ITGA1-associated signaling pathways in pediatric cancers. In glioma, ITGA1 contributes to treatment resistance by promoting cell survival signaling. Increased ITGA1 activity supports activation of the PI3K/AKT pathway and anti-apoptotic signaling through Bcl-2, promoting resistance toward temozolomide. The involvement of ITGA1 in drug resistance highlights its role in regulating tumor cell adaptation to therapeutic stress.
The first pathway begins with a P450 enzyme, ibogamine-10-hydroxylase (I10H), and methylation of noribogaine-10-Ο-methyltransferase (N10OMT) to produce (-)-voacangine. Polyneudridine aldehyde esterase-like 1 (PNAE1) and a spontaneous decarboxylation can convert (-)-voacangine to (-)-ibogaine. The second pathway consists of PNAE1 and the spontaneous decarboxylation occurring first to yield (-)-ibogamine, then the reaction of I10H-mediated hydroxylation and N10OMT-catalyzed O-methylation to produce (-)-ibogaine.
=== Taxes on social security === On July 3, Social Security Administration sent an email suggesting that federal income taxes on Social Security benefits would be eliminated under the bill, but tax experts stated the message was misleading. The law introduces a temporary $6,000 tax deduction for persons aged 65 and older with a certain income, which can reduce federal tax liability from that otherwise owed, but the law does not directly eliminate the taxes on Social Security benefits, which remain in effect under 26 U.S.C. § 86. All revenue from the taxation of Social Security benefits is earmarked for reinvestment into the Social Security Trust Fund, so the deduction would accelerate the insolvency of the Social Security benefits system by limiting this revenue stream.
The character was introduced during the serial's 2019 season finale, which saw several characters held hostage at gunpoint in the local hospital. Kipa-Williams explained that Ari's boss sends him to the hospital after he sustains a cut to his arm while working on a construction site. Shortly after Ari arrives, armed men from the Ouroboros gang take everyone on that floor hostage. When the hostages are rounded up, Ari is forced to sit next to "a terrified" Marilyn Chambers (Emily Symons), who he instantly tries to help and reassure. Kipa-Williams told Rachel Lucas of What's on TV: "Ari comes from a past where he's not unfamiliar with bad guys. He's relatively calm, he's very aware and he's strategizing a way to get the hostages – or himself – out." Knowing that they need to gain "control of the situation", Ari teams up with Mason Morgan (Orpheus Pledger) and they devise an escape plan. Ari leads most of the hostages out of the building, while Mason tries to distract the gunmen, which results in his death when he is shot. Kipa-Williams likened the filming of the storyline to a feature film, saying "We spent quite a number of days in the hospital set and at the exterior of the hospital so my first few days filming were quite intense. It was a really nice welcome!" The actor was also grateful that he shared his first scenes with Symons. After the scenes aired, it was confirmed that Ari's family would soon be introduced and that they would be hiding some secrets. The Paratas later move in with Marilyn and her husband John Palmer (Shane Withington).
Amifostine is an organic thiophosphate prodrug which is hydrolysed in vivo by alkaline phosphatase to the active cytoprotective thiol metabolite, WR-1065. The selective protection of non-malignant tissues is believed to be due to higher alkaline phosphatase activity, higher pH, and vascular permeation of normal tissues. Amifostine can be administered intravenously or subcutaneously after reconstitution with normal saline. Infusions lasting less than 15 minutes decrease the risk of adverse effects. The patient should be well-hydrated prior to administration.
Sources: en.wikipedia.org
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
== Occurrence == The compound is produced by human pathogens such as Aspergillus fumigatus, and also by species of Trichoderma and Penicillium. Gliotoxin has also been reported from yeasts of the genus Candida, but results from other studies have cast doubt on the production of this metabolite by Candida fungi. Gliotoxin is not produced by nonpathogenic A. fischeri although A.fischeri contains a gene cluster that is homologous to the gliotoxin gene cluster found in the pathogenic A. fumigatus. Gliotoxin contributes to the pathogenicity of opportunistic fungi by suppressing the immune system response of its host. Gliotoxin additionally possesses fungicidal and bacteriostatic properties, which indicates that it likely plays an important self defense role against bacteria and other fungi for the fungi that produce gliotoxin. Exposure of A. fumigatus to exogenous gliotoxin resulted in aberrant protein expression, especially in those strains that lacked the self-protection protein GliT. There is additional evidence for differential gliotoxin sensitivities amongst fungi including Aspergillus flavus, Fusarium graminearum, and Aspergillus oryzae.
House of Karađorđević: Grand Master of the Royal Order of Saint Prince Lazarus House of Karađorđević: Grand Master of the Royal Order of the Star of Karađorđe House of Karađorđević: Grand Master of the Royal Order of the White Eagle House of Karađorđević: Grand Master of the Royal Order of the Crown House of Karađorđević: Grand Master of the Royal Order of Saint Sava
== Inhibitors == Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.
Sources: en.wikipedia.org
Although various different techniques of acupuncture practice have emerged, the method used in traditional Chinese medicine (TCM) seems to be the most widely adopted in the US. Traditional acupuncture involves needle insertion, moxibustion, and cupping therapy, and may be accompanied by other procedures such as feeling the pulse and other parts of the body and examining the tongue. Traditional acupuncture involves the belief that a "life force" (qi) circulates within the body in lines called meridians. The main methods practiced in the UK are TCM and Western medical acupuncture. The term Western medical acupuncture is used to indicate an adaptation of TCM-based acupuncture which focuses less on TCM. The Western medical acupuncture approach involves using acupuncture after a medical diagnosis. Limited research has compared the contrasting acupuncture systems used in various countries for determining different acupuncture points, and thus there is no defined standard for acupuncture points. In traditional acupuncture, the acupuncturist decides which points to treat by observing and questioning the patient to make a diagnosis according to the tradition used. In TCM, the four diagnostic methods are: inspection, auscultation and olfaction, inquiring, and palpation. Inspection focuses on the face and particularly on the tongue, including analysis of the tongue placement, size, shape, tension, color and coating, and the absence or presence of teeth marks around the edge. Auscultation and olfaction involve listening for particular sounds, such as wheezing, and observing body odor.
Inherited – hereditary motor neuropathies, Charcot–Marie–Tooth disease, and hereditary neuropathy with liability to pressure palsy Acquired – diabetes mellitus, vascular neuropathy, alcohol use disorder, vitamin E deficiency, and vitamin B12 deficiency
== References == CDBaby.com BBC Radio 2 Interview (The Weekender with Matthew Wright - 3rd Nov 2006) The Times Newspaper (UK): Knowledge Section (Saturday 26 Nov 2006) Future Music Magazine interview (Nov 2005)
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.